Back

Effectiveness of Bivalent Boosters Over Nine and Half Months in Nebraska

2023-12-04 infectious diseases Title + abstract only
View on medRxiv
Show abstract

On September 1, 2022, Moderna and Pfizer-BioNTech bivalent vaccines replaced existing monovalent vaccines as booster doses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for persons aged 12 and older in the United States. We assessed the effectiveness of these bivalent boosters against Omicron infection and severe outcomes (COVID-19 hospitalization and death) over a 9.5-month period using line-level data from the state of Nebraska. We found that the relative effectiveness o...

Predicted journal destinations